A Comparative Analysis of the Serum Paraoxonase (PON1) Activity and the Concentration of Parameters of Lipid Profile after 3 Months of Statin Therapy
DOI:
https://doi.org/10.37506/hm9qbz10Keywords:
Paraoxonase I, High density lipoprotein, statin therapy, cardiac patients, follow-up.Abstract
Background: Human serum paraoxonase (PON1) residing on HDL can prevent the oxidation of low density
lipoprotein (LDL), the initiating factor in atherosclerosis. Statins are commonly used to treat dyslipidemia,
aknown risk factor for coronary artery disease (CAD).The aim of the studyis to evaluate the alterations in the
concentrationof PON1 along with that of other parameters of lipid profile in patients of CAD before and after 3 months of statin therapy.
Materials and Methods: The study included 30 new patients who were put on statin therapy following the
diagnosis of acute coronary syndrome. The activity of PON1 (units-IU/L) and the concentration of lipid profile
parameters (units-mg/dl) were estimated before starting statin therapy and again after three months. Patients with co-morbidities like diabetes, kidney disease, liver disease and other cardiac diseases of infectious aetiology were excluded.
Results and Analysis: As expected, both PON1 and HDL have increased after 3 months. There was a statistically significant increase in both PON1 (p<0.05)and HDL (p<0.001) and a decrease (p <0.05, also statistically significant)in LDL after 3 months of statin therapy.
Conclusion: This knowledge may be exploited in the follow up CAD patients. The increase in PONI and the
similar increase in HDL after 3 months of statin therapy may be exploited in the follow-up of cardiac patients.
References
Parthasarathy S, Barnett J, Fong LG. High-density
lipoprotein inhibits the oxidative modification
of low-density lipoprotein. Biochim Biophys
Acta. . 1990; 1044: 275–283.
Steinberg D, Parthasarathy S, Carew TE, Khoo JC,
Witztum JL. Beyond cholesterol modifications of lowdensity
lipoprotein that increase its atherogenicity.
N Engl J Med. . 1989; 320: 915–924.
Wang F, Liu Y, Cong Y, Li P, Li Y, Yan Z, et al. Shift
of the interconnection from the reaction system of
paraoxonase 1 to the peroxidation reaction system
of myeloperoxidase with HDL-C levels: A marker of
atherosclerosis in patients with normal cholesterol
levels. Clin Chim Acta.2015; 438: 370-5.
Ikeda Y, Suehiro T, Itahara T, Inui Y,
Chikazawa H, Inoue M, et al. Human serum
paraoxonase concentration predicts cardiovascular
mortality in hemodialysis patients. Clin Nephrol
;67:358–65.
M.J. Chapman, Are the effects of statins on HDLcholesterol
clinically relevant?, European Heart
Journal Supplements, Volume 6, Issue suppl_C, 1 July
, Pages C58–C63, https://doi.org/10.1016/j.
ehjsup.2004.04.002
Stroes E. Statins and LDL-cholesterol lowering: an
overview. Curr Med Res Opin. 2005;21 Suppl 6:S9-16.
doi: 10.1185/030079905X59102. PMID: 16138936.
Feingold KR. Cholesterol Lowering Drugs. [Updated
Mar 30]. In: Feingold KR, Anawalt B, Boyce A,
et al., editors. Endotext [Internet]. South Dartmouth
(MA): MDText.com, Inc.; 2000-. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK395573/
Mackness B, Durrington PN, Mackness MI. Human
serum paraoxonase. Gen Pharmac 1998;31:329–36.
Davidson WS, Silva RAGD, Chantepie S, Lagor WR,
Chapman MJ, Kontush A. Proteomic analysis of defined
HDL subpopulations reveals particle-specific protein
clusters—Relevance to antioxidative function.
Arteriioscler Thromb Vasc Biol 2009;29:870–6.
Rajkovic MG, Rumora L, Barisic K. The paraoxonase 1,
and 3 in humans. Biochemia Medica 2011;21:122–30.
Rodriguez-Sanabria F, Rull A, Beltran-Debon R,
Aragones G, Camps J, Mackness B, et al. Tissue
distribution and expression of paraoxonases and
chemokines in the mouse: the ubiquitous and joint
localisation suggest a systemic and coordinated role. J
Mol Histol 2010;41:379–86.
Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3,
oxidative stress, and macrophage foam cell formation
during atherosclerosis development. Free Radic Biol
Med 2004;37:1304–16.
Reddy ST, Devarajan A, Bourquard N, Shih D,
Fogelman AM. Is it just paraoxonase 1 or are other
members of the paraoxonase gene family implicated in
atherosclerosis? Curr Opin Lipidol 2008;19:405–8.
Deakin SP, James RW. Genetic and environmental
factors modulating serum concentrations and activities
of the antioxidant enzyme paraoxonase-1. Clin Sci
;107:435–47
Mackness MI, Arrol S, Durrington PN. Paraoxonase
prevents accumulation of lipoperoxides in low-density
lipoprotein. FEBS Letts 1991;286:152–4.
Mackness MI, Arrol S, Abbott CA, Durrington PN.
Protection of low-density lipoprotein against oxidative
modification by high-density lipoprotein associated
paraoxonase. Atherosclerosis 1993;104:129–35.
Tavori H, Aviram M, Khatib S, Musa R, Mannheim D,
Karmeli R, et al. Paraoxonase 1 protects macrophages
from atherogenicity of a specific triglyceride isolated
from human carotid lesion. Free Rad Biol Med
;51:234–42.
Hine D, Mackness B, Mackness M. Co-incubation
of PON1, APO A1 and LCAT increases the timeHDL is able to prevent LDL oxidation. IUBMB Life
;64:157– 61.
Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M.
Paraoxonase 1 inhibits oxidised LDL-induced MCP-1
production by endothelial cells. BBRC 2004;318:680–3.
Mackness B, Quarck R, Verreth W, Mackness M,
Holvoet P. Human paraoxonase-1 overexpression
inhibits atherosclerosis in a mouse model of
metabolic syndrome. Arterioscler Thromb Vasc Biol
;26:1545–50.
Jakubowski H. Homocysteine thiolactone: metabolic
origin and protein homocysteinylation in humans. J
Nutr 2000;130:377S–81S.
Jakubowski H. Calcium-dependent human serum
homocysteine thiolactone hydrolase—a protective
mechanism against protein s-homocysteinylation. J
Biol Chem 2000;275:3957–62.
Tang WHW, Hartiala J, Fan Y, Wu Y, Stewart AFR,
Erdmann J, et al. Clinical and genetic association of
serum paraoxonase and arylesterase activities with
cardiovascular risk. Arterioscler Thromb Vasc Biol
;32:2803–12.
Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS,
Richter RJ, Schellenberg GD. Furlong, C.E. Paraoxonase
(PON1) phenotype is a better predictor of vascular
disease than is PON1192 or PON155 genotype.
Arterioscl Thromb Vasc Biol 2000;20:2441–7.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.